ZyVersa Therapeutics Inc ZVSA shares are trading higher by 126% to $1.81 Monday, despite a lack of company-specific news for the session. The stock is trading higher amid ongoing volatility after the company last week released a white paper titled “Inflammasome ASC Inhibitor IC 100, Promising Therapeutic Potential For Neurological Diseases.”
The paper discusses how activating multiple inflammasomes can contribute to neurological diseases and presents data from preclinical research on Inflammasome ASC Inhibitor IC 100. This research, led by Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari at the University of Miami Miller School of Medicine, shows promising results in animal models and tissue cultures of various neurological conditions including multiple sclerosis, Alzheimer’s disease, traumatic brain injury and spinal cord injury.
The company plans to file an IND in late 2024 and initiate a phase 1 clinical trial in early 2025 for IC 100, aiming to address the unmet medical needs of patients with inflammatory and renal diseases.
See Also: Why Warren Buffett Likes American Oil Companies
How To Buy ZVSA Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in ZyVersa Therapeutics’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, ZVSA has a 52-week high of $96.85 and a 52-week low of $0.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
